PowerShares DWA Healthcare Momentum ETF

Most Recent

  • uploads///Ignyta risks
    Company & Industry Overviews

    Ignyta and Its Key Risks in 2018

    In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

    By Kenneth Smith
  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
  • uploads///chart
    Macroeconomic Analysis

    A Comparative Analysis of PTH and DWAQ

    PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    An Overview of PTH’s Pharmaceutical and Biotechnology Holdings

    PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.

    By Ivan Kading
  • uploads///md pm
    Earnings Report

    MEDNAX Revenue and Income Rose After 3Q15 Results

    MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.

    By Gabriel Kane
  • uploads///Chart
    Macroeconomic Analysis

    A Comparison of a Momentum ETF and the Volatility Index

    Momentum stocks are only affected by a significant rise or fall of the VIX, unlike minimum volatility stocks, which are affected by even a minor change in the VIX.

    By Ivan Kading
  • uploads///gks COO
    Earnings Report

    Cooper Companies Shows Strong Relative Earnings Compared to Peers

    The PowerShares DWA Healthcare Momentum Portfolio (PTH) invests 4.54% of its holdings in Cooper.

    By Gabriel Kane
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///chart
    Macroeconomic Analysis

    Comparing PTH to Its Benchmark, the S&P 500 Index

    The five-year annualized return of PTH is 21.0%. SPY comes in 15.75%. Clearly, PTH’s smart beta strategy has outperformed the market.

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    An Overview of PTH Holdings

    Top holdings for PTH include Regeneron Pharmaceuticals (REGN), Allergan (AGN), Cigna (CI), Incyte (INCY), and Medivation (MDVN).

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    Comparing PTH to Its Peers, PBE and PJP

    The performance of PTH tracks more closely to PBE than PJP.

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    PTH: A Momentum-Based ETF

    PTH seeks to mimic the investment results of the Dorsey Wright Healthcare Technical Leaders Index, selecting stocks based on their momentum.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.